相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Quantitative [18F]FMISO PET Imaging Shows Reduction of Hypoxia Following Trastuzumab in a Murine Model of HER2+Breast Cancer
Anna G. Sorace et al.
MOLECULAR IMAGING AND BIOLOGY (2017)
Imaging biomarker roadmap for cancer studies
James P. B. O'Connor et al.
NATURE REVIEWS CLINICAL ONCOLOGY (2017)
Efficacy of PD-1 Blockade Is Potentiated by Metformin-Induced Reduction of Tumor Hypoxia
Nicole E. Scharping et al.
CANCER IMMUNOLOGY RESEARCH (2017)
Evolution of [18F]fluorodeoxyglucose and [18F]fluoroazomycin arabinoside PET uptake distributions in lung tumours during radiation therapy
Dario Di Perri et al.
ACTA ONCOLOGICA (2017)
Oxygen-Enhanced MRI Accurately Identifies, Quantifies, and Maps Tumor Hypoxia in Preclinical Cancer Models
James P. B. O'Connor et al.
CANCER RESEARCH (2016)
Effects of metformin on survival outcomes of lung cancer patients with type 2 diabetes mellitus: a meta-analysis
R. -H. Tian et al.
CLINICAL & TRANSLATIONAL ONCOLOGY (2016)
Multiparametric imaging of patient and tumour heterogeneity in non-small-cell lung cancer: quantification of tumour hypoxia, metabolism and perfusion
Wouter van Elmpt et al.
EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING (2016)
Tumor Hypoxia Response After Targeted Therapy in EGFR-Mutant Non-Small Cell Lung Cancer: Proof of Concept for FMISO-PET
Nils D. Arvold et al.
TECHNOLOGY IN CANCER RESEARCH & TREATMENT (2016)
Oxygen-Enhanced MRI Is a Major Advance in Tumor Hypoxia Imaging
Mark W. Dewhirst et al.
CANCER RESEARCH (2016)
Hypoxia Potentiates the Radiation-Sensitizing Effect of Olaparib in Human Non-Small Cell Lung Cancer Xenografts by Contextual Synthetic Lethality
Yanyan Jiang et al.
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS (2016)
Clinicopathological and prognostic significance of hypoxia-inducible factor-1 alpha in lung cancer: a systematic review with meta-analysis
Sheng-li Yang et al.
JOURNAL OF HUAZHONG UNIVERSITY OF SCIENCE AND TECHNOLOGY-MEDICAL SCIENCES (2016)
Prognostic significance of hypoxic PET using 18F-FAZA and 62Cu-ATSM in non-small-cell lung cancer
Tomonari Kinoshita et al.
LUNG CANCER (2016)
Clinical development of new drug-radiotherapy combinations
Ricky A. Sharma et al.
NATURE REVIEWS CLINICAL ONCOLOGY (2016)
Prognostic value of blood-biomarkers related to hypoxia, inflammation, immune response and tumour load in non-small cell lung cancer - A survival model with external validation
Sara Carvalho et al.
RADIOTHERAPY AND ONCOLOGY (2016)
The anti-malarial atovaquone increases radiosensitivity by alleviating tumour hypoxia
Thomas M. Ashton et al.
NATURE COMMUNICATIONS (2016)
Protocol for the isotoxic intensity modulated radiotherapy (IMRT) in stage III non-small cell lung cancer (NSCLC): a feasibility study
Kate Haslett et al.
BMJ OPEN (2016)
Reproducibility of 18F-fluoromisonidazole intratumour distribution in non-small cell lung cancer
Milan Grkovski et al.
EJNMMI RESEARCH (2016)
An exploratory study of volumetric analysis for assessing tumor response with 18F-FAZA PET/CT in patients with advanced non-small-cell lung cancer (NSCLC)
Gerald S. M. A. Kerner et al.
EJNMMI RESEARCH (2016)
A phase III randomized trial of adding topical nitroglycerin to first-line chemotherapy for advanced nonsmall-cell lung cancer: the Australasian lung cancer trials group NITRO trial
A. Davidson et al.
ANNALS OF ONCOLOGY (2015)
A randomized phase II study comparing paclitaxel-carboplatin-bevacizumab with or without nitroglycerin patches in patients with stage IV nonsquamous nonsmall-cell lung cancer: NVALT12 (NCT01171170)aEuro
A. -M. C. Dingemans et al.
ANNALS OF ONCOLOGY (2015)
AKR1C3 is a biomarker of sensitivity to PR-104 in preclinical models of T-cell acute lymphoblastic leukemia
Donya Moradi Manesh et al.
BLOOD (2015)
Validation of functional imaging as a biomarker for radiation treatment response
C. Jentsch et al.
BRITISH JOURNAL OF RADIOLOGY (2015)
Parallel phase Ib studies of two schedules of buparlisib (BKM120) plus carboplatin and paclitaxel (q21 days or q28 days) for patients with advanced solid tumors
David M. Hyman et al.
CANCER CHEMOTHERAPY AND PHARMACOLOGY (2015)
Prognostic value of 18F-fluoroazomycin arabinoside PET/CT in patients with advanced non-small-cell lung cancer
Tsuneo Saga et al.
CANCER SCIENCE (2015)
Preclinical Assessment of Efficacy of Radiation Dose Painting Based on Intratumoral FDG-PET Uptake
Daniela Trani et al.
CLINICAL CANCER RESEARCH (2015)
TH-302 in Combination with Radiotherapy Enhances the Therapeutic Outcome and Is Associated with Pretreatment [18F]HX4 Hypoxia PET Imaging
Sarah G. J. A. Peeters et al.
CLINICAL CANCER RESEARCH (2015)
Repeatability of hypoxia PET imaging using [18F]HX4 in lung and head and neck cancer patients: a prospective multicenter trial
Catharina M. L. Zegers et al.
EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING (2015)
Metronomic vinorelbine: Anti-angiogenic activity in vitro in normoxic and severe hypoxic conditions, and severe hypoxia-induced resistance to its anti-proliferative effect with reversal by Akt inhibition
L. Mavroeidis et al.
INTERNATIONAL JOURNAL OF ONCOLOGY (2015)
A Comparative Study of the Hypoxia PET Tracers [18F] HX4, [18F] FAZA, and [18F] FMISO in a Preclinical Tumor Model
Sarah G. J. A. Peeters et al.
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS (2015)
Global surveillance of cancer survival 1995-2009: analysis of individual data for 25 676 887 patients from 279 population-based registries in 67 countries (CONCORD-2)
Claudia Allemani et al.
LANCET (2015)
Standard-dose versus high-dose conformal radiotherapy with concurrent and consolidation carboplatin plus paclitaxel with or without cetuximab for patients with stage IIIA or IIIB non-small-cell lung cancer (RTOG 0617): a randomised, two-by-two factorial phase 3 study
Jeffrey D. Bradley et al.
LANCET ONCOLOGY (2015)
IAEA-HypoX. A randomized multicenter study of the hypoxic radiosensitizer nimorazole concomitant with accelerated radiotherapy in head and neck squamous cell carcinoma
Mohamed A. Hassan Metwally et al.
RADIOTHERAPY AND ONCOLOGY (2015)
PET-based dose painting in non-small cell lung cancer: Comparing uniform dose escalation with boosting hypoxic and metabolically active sub-volumes
Aniek J. G. Even et al.
RADIOTHERAPY AND ONCOLOGY (2015)
Hypoxia as a Cause of Treatment Failure in Non-Small Cell Carcinoma of the Lung
Odd Terje Brustugun
SEMINARS IN RADIATION ONCOLOGY (2015)
Circulating microRNA Biomarkers as Liquid Biopsy for Cancer Patients: Pros and Cons of Current Assays
Shigeshi Ono et al.
JOURNAL OF CLINICAL MEDICINE (2015)
Prognostic Impact of Hypoxia-Inducible miRNA-210 in Patients with Lung Adenocarcinoma
Jun Osugi et al.
JOURNAL OF ONCOLOGY (2015)
Imaging Intratumor Heterogeneity: Role in Therapy Response, Resistance, and Clinical Outcome
James P. B. O'Connor et al.
CLINICAL CANCER RESEARCH (2015)
Targeting tumour hypoxia to prevent cancer metastasis. From biology, biosensing and technology to drug development: the METOXIA consortium
Erik O. Pettersen et al.
JOURNAL OF ENZYME INHIBITION AND MEDICINAL CHEMISTRY (2015)
The tumour microenvironment after radiotherapy: mechanisms of resistance and recurrence
Holly E. Barker et al.
NATURE REVIEWS CANCER (2015)
Defining normoxia, physoxia and hypoxia in tumours-implications for treatment response
S. R. McKeown
BRITISH JOURNAL OF RADIOLOGY (2014)
In Vivo Quantification of Hypoxic and Metabolic Status of NSCLC Tumors Using [18F]HX4 and [18F]FDG-PET/CT Imaging
Catharina M. L. Zegers et al.
CLINICAL CANCER RESEARCH (2014)
The Meaning, Measurement and Modification of Hypoxia in the Laboratory and the Clinic
E. M. Hammond et al.
CLINICAL ONCOLOGY (2014)
A prospective clinical study of 18 F-FAZA PET-CT hypoxia imaging in head and neck squamous cell carcinoma before and during radiation therapy
Stephanie Servagi-Vernat et al.
EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING (2014)
The Tumor Radiobiology of SRS and SBRT: Are More Than the 5 Rs Involved?
J. Martin Brown et al.
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS (2014)
Parametric Methods for Quantification of 18F-FAZA Kinetics in Non-Small Cell Lung Cancer Patients
Eline E. Verwer et al.
JOURNAL OF NUCLEAR MEDICINE (2014)
Membrane Carbonic Anhydrase IX Expression and Relapse Risk in Resected Stage I-II Non-Small-Cell Lung Cancer
David J. Stewart et al.
JOURNAL OF THORACIC ONCOLOGY (2014)
Tumour genomic and microenvironmental heterogeneity for integrated prediction of 5-year biochemical recurrence of prostate cancer: a retrospective cohort study
Emilie Lalonde et al.
LANCET ONCOLOGY (2014)
Positive prognostic impact of miR-210 in non-small cell lung cancer
Marte Eilertsen et al.
LUNG CANCER (2014)
Randomized, double-blind phase II study to compare nitroglycerin plus oral vinorelbine plus cisplatin with oral vinorelbine plus cisplatin alone in patients with stage IIIB/IV non-small cell lung cancer (NSCLC)
N. Reinmuth et al.
LUNG CANCER (2014)
Noninvasive Tumor Hypoxia Measurement Using Magnetic Resonance Imaging in Murine U87 Glioma Xenografts and in Patients with Glioblastoma
Inna V. Linnik et al.
MAGNETIC RESONANCE IN MEDICINE (2014)
Hypoxia Increases Gefitinib-Resistant Lung Cancer Stem Cells through the Activation of Insulin-Like Growth Factor 1 Receptor
Akiko Murakami et al.
PLOS ONE (2014)
Dynamics of tumor hypoxia assessed by 18F-FAZA PET/CT in head and neck and lung cancer patients during chemoradiation: Possible implications for radiotherapy treatment planning strategies
Vikram R. Bollineni et al.
RADIOTHERAPY AND ONCOLOGY (2014)
Phase II study. Concurrent chemotherapy and radiotherapy with nitroglycerin in locally advanced non-small cell lung cancer
Oscar Arrieta et al.
RADIOTHERAPY AND ONCOLOGY (2014)
A pilot 'window of opportunity' neoadjuvant study of metformin in localised prostate cancer
A. M. Joshua et al.
PROSTATE CANCER AND PROSTATIC DISEASES (2014)
Bioreductive prodrugs as cancer therapeutics: targeting tumor hypoxia
Christopher P. Guise et al.
CHINESE JOURNAL OF CANCER (2014)
Patterns of locoregional failure in stage III non-small cell lung cancer treated with definitive chemoradiation therapy
Shalini Garg et al.
PRACTICAL RADIATION ONCOLOGY (2014)
Prognostic Role of Hypoxic Inducible Factor Expression in Non-small Cell Lung Cancer: A Meta-analysis
Cong Li et al.
ASIAN PACIFIC JOURNAL OF CANCER PREVENTION (2013)
A 26-Gene Hypoxia Signature Predicts Benefit from Hypoxia-Modifying Therapy in Laryngeal Cancer but Not Bladder Cancer
Amanda Eustace et al.
CLINICAL CANCER RESEARCH (2013)
Reprogramming Metabolism with Metformin Improves Tumor Oxygenation and Radiotherapy Response
Vanessa E. Zannella et al.
CLINICAL CANCER RESEARCH (2013)
Prospective technical validation and assessment of intra-tumour heterogeneity of a low density array hypoxia gene profile in head and neck squamous cell carcinoma
Guy N. J. Betts et al.
EUROPEAN JOURNAL OF CANCER (2013)
Pharmacokinetic analysis of [18F]FAZA in non-small cell lung cancer patients
Eline E. Verwer et al.
EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING (2013)
Prognostic significance of serum microRNA-210 levels in nonsmall-cell lung cancer
Zhi-Hong Li et al.
JOURNAL OF INTERNATIONAL MEDICAL RESEARCH (2013)
Imaging of hypoxia with 18F-FAZA PET in patients with locally advanced non-small cell lung cancer treated with definitive chemoradiotherapy
Mateya E. Trinkaus et al.
JOURNAL OF MEDICAL IMAGING AND RADIATION ONCOLOGY (2013)
Interobserver Agreement of Qualitative Analysis and Tumor Delineation of 18F-Fluoromisonidazole and 3′-Deoxy-3′-18F-Fluorothymidine PET Images in Lung Cancer
Sebastien Thureau et al.
JOURNAL OF NUCLEAR MEDICINE (2013)
Predicting outcomes in radiation oncology-multifactorial decision support systems
Philippe Lambin et al.
NATURE REVIEWS CLINICAL ONCOLOGY (2013)
Computed 88% TCP dose for SBRT of NSCLC from tumour hypoxia modelling
Ruggero Ruggieri et al.
PHYSICS IN MEDICINE AND BIOLOGY (2013)
Hypoxia imaging with [18F]HX4 PET in NSCLC patients: Defining optimal imaging parameters
Catharina M. L. Zegers et al.
RADIOTHERAPY AND ONCOLOGY (2013)
Interaction of EGFR with the tumour microenvironment: Implications for radiation treatment
Monique M. Nijkamp et al.
RADIOTHERAPY AND ONCOLOGY (2013)
MiR-210 promotes a hypoxic phenotype and increases radioresistance in human lung cancer cell lines
S. Grosso et al.
CELL DEATH & DISEASE (2013)
Evaluation of Diabetic Patients with Breast Cancer Treated with Metformin during Adjuvant Radiotherapy
Adam Ferro et al.
INTERNATIONAL JOURNAL OF BREAST CANCER (2013)
PR-104 a bioreductive pre-prodrug combined with gemcitabine or docetaxel in a phase Ib study of patients with advanced solid tumours
Mark J. McKeage et al.
BMC CANCER (2012)
Targeting radiation-resistant hypoxic tumour cells through ATR inhibition
I. M. Pires et al.
BRITISH JOURNAL OF CANCER (2012)
Hypoxia induces gefitinib resistance in non-small-cell lung cancer with both mutant and wild-type epidermal growth factor receptors
Kunihiko Minakata et al.
CANCER SCIENCE (2012)
Prognostic Significance of Plasma Osteopontin in Patients with Locoregionally Advanced Head and Neck Squamous Cell Carcinoma Treated on TROG 02.02 Phase III Trial
Annette M. Lim et al.
CLINICAL CANCER RESEARCH (2012)
Selective Tumor Hypoxia Targeting by Hypoxia-Activated Prodrug TH-302 Inhibits Tumor Growth in Preclinical Models of Cancer
Jessica D. Sun et al.
CLINICAL CANCER RESEARCH (2012)
Elusive Goal of Targeting Tumor Hypoxia for Therapeutic Gain
Lester Peters et al.
JOURNAL OF CLINICAL ONCOLOGY (2012)
Patterns of disease recurrence after stereotactic ablative radiotherapy for early stage non-small-cell lung cancer: a retrospective analysis
Sashendra Senthi et al.
LANCET ONCOLOGY (2012)
Trends in incidence of small cell lung cancer and all lung cancer
Sharma P. Riaz et al.
LUNG CANCER (2012)
Promise and pitfalls of quantitative imaging in oncology clinical trials
Brenda F. Kurland et al.
MAGNETIC RESONANCE IMAGING (2012)
Dynamic contrast-enhanced-MRI of tumor hypoxia
Tormod A. M. Egeland et al.
MAGNETIC RESONANCE IN MEDICINE (2012)
Hypoxia-activated prodrugs forge ahead in cancer
Jim Kling
NATURE BIOTECHNOLOGY (2012)
Imaging hypoxia to improve radiotherapy outcome
Michael R. Horsman et al.
NATURE REVIEWS CLINICAL ONCOLOGY (2012)
A modified hypoxia-based TCP model to investigate the clinical outcome of stereotactic hypofractionated regimes for early stage non-small-cell lung cancer (NSCLC)
L. Strigari et al.
MEDICAL PHYSICS (2012)
Assessment of hypoxia and radiation response in intramuscular experimental tumors by dynamic contrast-enhanced magnetic resonance imaging
Kirsti Marie Ovrebo et al.
RADIOTHERAPY AND ONCOLOGY (2012)
Exploratory prospective trial of hypoxia-specific PET imaging during radiochemotherapy in patients with locally advanced head-and-neck cancer
Daniel Zips et al.
RADIOTHERAPY AND ONCOLOGY (2012)
FAZA PET/CT hypoxia imaging in patients with squamous cell carcinoma of the head and neck treated with radiotherapy: Results from the DAHANCA 24 trial
Lise Sakso Mortensen et al.
RADIOTHERAPY AND ONCOLOGY (2012)
The PET-boost randomised phase II dose-escalation trial in non-small cell lung cancer
Wouter van Elmpt et al.
RADIOTHERAPY AND ONCOLOGY (2012)
Hypoxia Gene Expression Signatures as Prognostic and Predictive Markers in Head and Neck Radiotherapy
Kasper Toustrup et al.
SEMINARS IN RADIATION ONCOLOGY (2012)
Hypoxia-induced cisplatin resistance is reversible and growth rate independent in lung cancer cells
Christoph Wohlkoenig et al.
CANCER LETTERS (2011)
Development of a Hypoxia Gene Expression Classifier with Predictive Impact for Hypoxic Modification of Radiotherapy in Head and Neck Cancer
Kasper Toustrup et al.
CANCER RESEARCH (2011)
Hallmarks of Cancer: The Next Generation
Douglas Hanahan et al.
CELL (2011)
Phase 1 Study of the Safety, Tolerability, and Pharmacokinetics of TH-302, a Hypoxia-Activated Prodrug, in Patients with Advanced Solid Malignancies
Glen J. Weiss et al.
CLINICAL CANCER RESEARCH (2011)
Hypoxia-mediated drug resistance: Novel insights on the functional interaction of HIFs and cell death pathways
Nadine Rohwer et al.
DRUG RESISTANCE UPDATES (2011)
Simultaneous positron emission tomography (PET) assessment of metabolism with F-18-fluoro-2-deoxy-D-glucose (FDG), proliferation with F-18-fluoro-thymidine (FLT), and hypoxia with (18)fluoro-misonidazole (F-miso) before and during radiotherapy in patients with non-small-cell lung cancer (NSCLC): A pilot study
Pierre Vera et al.
RADIOTHERAPY AND ONCOLOGY (2011)
Targeting hypoxia in cancer therapy
William R. Wilson et al.
NATURE REVIEWS CANCER (2011)
High levels of carbonic anhydrase IX in tumour tissue and plasma are biomarkers of poor prognostic in patients with non-small cell lung cancer
M. Ilie et al.
BRITISH JOURNAL OF CANCER (2010)
Large meta-analysis of multiple cancers reveals a common, compact and highly prognostic hypoxia metagene
F. M. Buffa et al.
BRITISH JOURNAL OF CANCER (2010)
Contextual Synthetic Lethality of Cancer Cell Kill Based on the Tumor Microenvironment
Norman Chan et al.
CANCER RESEARCH (2010)
Comparison of F-18-Fluoroerythronitroimidazole and F-18-Fluorodeoxyglucose Positron Emission Tomography and Prognostic Value in Locally Advanced Non-Small-Cell Lung Cancer
Ling Li et al.
CLINICAL LUNG CANCER (2010)
IONIZING RADIATION ACTIVATES AMP-ACTIVATED KINASE (AMPK): A TARGET FOR RADIOSENSITIZATION OF HUMAN CANCER CELLS
Toran Sanli et al.
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS (2010)
Effect of Chronic Intermittent Hypoxia on Biological Behavior and Hypoxia-Associated Gene Expression in Lung Cancer Cells
Yonglei Liu et al.
JOURNAL OF CELLULAR BIOCHEMISTRY (2010)
Tirapazamine, Cisplatin, and Radiation Versus Cisplatin and Radiation for Advanced Squamous Cell Carcinoma of the Head and Neck (TROG 02.02, HeadSTART): A Phase III Trial of the Trans-Tasman Radiation Oncology Group
Danny Rischin et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
Meta-Analysis of Concomitant Versus Sequential Radiochemotherapy in Locally Advanced Non-Small-Cell Lung Cancer
Anne Auperin et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
How to improve R&D productivity: the pharmaceutical industry's grand challenge
Steven M. Paul et al.
NATURE REVIEWS DRUG DISCOVERY (2010)
Modulating the tumor microenvironment to increase radiation responsiveness
Jayashree Karar et al.
CANCER BIOLOGY & THERAPY (2009)
New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)
E. A. Eisenhauer et al.
EUROPEAN JOURNAL OF CANCER (2009)
Initial results of hypoxia imaging using 1-α-D-(5-deoxy-5-[18F]-fluoroarabinofuranosyl)-2-nitroimidazole (18F-FAZA)
Ernst J. Postema et al.
EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING (2009)
PRELIMINARY STUDY OF OXYGEN-ENHANCED LONGITUDINAL RELAXATION IN MRI: A POTENTIAL NOVEL BIOMARKER OF OXYGENATION CHANGES IN SOLID TUMORS
James P. B. O'Connor et al.
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS (2009)
PROSPECTIVE TRIAL INCORPORATING PRE-/MID-TREATMENT [18F]-MISONIDAZOLE POSITRON EMISSION TOMOGRAPHY FOR HEAD-AND-NECK CANCER PATIENTS UNDERGOING CONCURRENT CHEMORADIOTHERAPY
Nancy Lee et al.
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS (2009)
Pathophysiologic Correlation Between 62Cu-ATSM and 18F-FDG in Lung Cancer
Talakad Goolaiah Lohith et al.
JOURNAL OF NUCLEAR MEDICINE (2009)
Dose Painting in Radiotherapy for Head and Neck Squamous Cell Carcinoma: Value of Repeated Functional Imaging with 18F-FDG PET, 18F-Fluoromisonidazole PET, Diffusion-Weighted MRI, and Dynamic Contrast-Enhanced MRI
Piet Dirix et al.
JOURNAL OF NUCLEAR MEDICINE (2009)
Serum Osteopontin Levels are Highly Prognostic for Survival in Advanced Non-small Cell Lung Cancer Results from JMTO LC 0004
Shun-Ichi Isa et al.
JOURNAL OF THORACIC ONCOLOGY (2009)
Identification of residual metabolic-active areas within individual NSCLC tumours using a pre-radiotherapy 18Fluorodeoxyglucose-PET-CT scan
Hugo J. W. L. Aerts et al.
RADIOTHERAPY AND ONCOLOGY (2009)
A Phase 1 Open-Label, Accelerated Dose-Escalation Study of the Hypoxia-Activated Prodrug AQ4N in Patients with Advanced Malignancies
Kyriakos P. Papadopoulos et al.
CLINICAL CANCER RESEARCH (2008)
Lower osteopontin plasma levels are associated with superior outcomes in advanced non-small-cell lung cancer patients receiving platinum-based chemotherapy: SWOG study S0003
Philip C. Mack et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
Enhanced local tumour control after single or fractionated radiation treatment using the hypoxic cell radiosensitizer doranidazole
Rumi Murata et al.
RADIOTHERAPY AND ONCOLOGY (2008)
Cycling hypoxia and free radicals regulate angiogenesis and radiotherapy response
Mark W. Dewhirst et al.
NATURE REVIEWS CANCER (2008)
HYPOXIA AND METABOLISM SERIES - TIMELINE The impact of O2 availability on human cancer
Jessica A. Bertout et al.
NATURE REVIEWS CANCER (2008)
Comparison of three carbon monoxide monitors for determination of smoking status in smokers and nonsmokers with and without COPD
Lieke Christenhusz et al.
JOURNAL OF AEROSOL MEDICINE-DEPOSITION CLEARANCE AND EFFECTS IN THE LUNG (2007)
Phase I/II trial of sequential chemoradiotherapy using a novel hypoxic cell radiosensitizer, doranidazole (PR-350), in patients with locally advanced non-small-cell lung cancer (WJTOG-0002)
Yasumasa Nishimura et al.
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS (2007)
Hypoxic radiosensitization: Adored and ignored
Jens Overgaard
JOURNAL OF CLINICAL ONCOLOGY (2007)
Chemical radiosensitizers for use in radiotherapy
P. Wardman
CLINICAL ONCOLOGY (2007)
Bioreductive drugs: from concept to clinic
S. R. McKeown et al.
CLINICAL ONCOLOGY (2007)
Hypoxia-imaging with 18F-misonidazole and PET:: Changes of kinetics during radiotherapy of head-and-neck cancer
Susanne Martina Eschmann et al.
RADIOTHERAPY AND ONCOLOGY (2007)
Relation of a hypoxia metagene derived from head and neck cancer to prognosis of multiple cancers
Stuart C. Winter et al.
CANCER RESEARCH (2007)
A microRNA signature of hypoxia
Ritu Kulshreshtha et al.
MOLECULAR AND CELLULAR BIOLOGY (2007)
Hypoxia: Importance in tumor biology, noninvasive measurement by imaging, and value of its measurement in the management of cancer therapy
James L. Tatum et al.
INTERNATIONAL JOURNAL OF RADIATION BIOLOGY (2006)
Prognostic significance of [18F]-misonidazole positron emission tomography-detected tumor hypoxia in patients with advanced head and neck cancer randomly assigned to chemoradiation with or without tirapazamine:: A substudy of Trans-Tasman Radiation Oncology Group study 98.02
D Rischin et al.
JOURNAL OF CLINICAL ONCOLOGY (2006)
Randomized phase II trial comparing nitroglycerin plus vinorelbine and cisplatin with vinorelbine and cisplatin alone in previously untreated stage IIIB/IV non-small-cell lung cancer
H Yasuda et al.
JOURNAL OF CLINICAL ONCOLOGY (2006)
Phase III trial of paclitaxel plus carboplatin with or without tirapazamine in advanced non-small-cell lung cancer: Southwest Oncology Group Trial S0003
SK Williamson et al.
JOURNAL OF CLINICAL ONCOLOGY (2005)
Reevaluation of the radiosensitizing effects of sanazole and nimorazole in vitro and in vivo
C Sugie et al.
JOURNAL OF RADIATION RESEARCH (2005)
Plasma osteopontin, hypoxia, and response to the hypoxia sensitiser nimorazole in radiotherapy of head and neck cancer: results from the DAHANCA 5 randomised double-blind placebo-controlled trial
J Overgaard et al.
LANCET ONCOLOGY (2005)
Phase II multicenter study of induction chemotherapy followed by concurrent efaproxiral (RSR13) and thoracic radiotherapy for patients with locally advanced non-small-cell lung cancer
H Choy et al.
JOURNAL OF CLINICAL ONCOLOGY (2005)
Epidermal growth factor and hypoxia-induced expression of CXC chemokine receptor 4 on non-small cell lung cancer cells is regulated by the phosphatidylinositol 3-kinase/PTEN/AKT/mammalian target of rapamycin signaling pathway and activation of hypoxia inducible factor-1α
RJ Phillips et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2005)
The concept of synthetic lethality in the context of anticancer therapy
WG Kaelin
NATURE REVIEWS CANCER (2005)
In vivo assessment of tumor hypoxia in lung cancer with 60Cu-ATSM
F Dehdashti et al.
EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING (2003)
Declining hemoglobin during chemoradiotherapy for locally advanced non-small cell lung cancer is significant
R MacRae et al.
RADIOTHERAPY AND ONCOLOGY (2002)
A novel strategy for NQO1 (NAD(P)H:quinone oxidoreductase, EC 1.6.99.2) mediated therapy of bladder cancer based on the pharmacological properties of EO9
GA Choudry et al.
BRITISH JOURNAL OF CANCER (2001)
Recursive partitioning analysis of 1999 radiation therapy oncology group (RTOG) patients with locally-advanced non-small-cell lung cancer (LA-NSCLC): Identification of five groups with different survival
M Werner-Wasik et al.
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS (2000)
Evaluation of 62Cu labeled diacetyl-bis(N4-methoylthiosemicarbazone) as a hypoxic tissue tracer in patients with lung cancer
N Takahashi et al.
ANNALS OF NUCLEAR MEDICINE (2000)
Tirapazamine plus cisplatin versus cisplatin in advanced non-small-cell lung cancer: A report of the international CATAPULT I study group
J von Pawel et al.
JOURNAL OF CLINICAL ONCOLOGY (2000)
分享论文
